2006 Annual Meeting | Therapeutic Poisoning: Immunosuppressive Therapy for Non-neoplastic Neurological Disease

Date Saturday 04/08/06

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Michael Glantz, MD, F�鶹��ýӳ��

Topic(s)

Learning Objectives Upon Completion:
Participants should be able to describe the currently available classes of immunosuppressive and myelosuppressive agents, their neurological and non-neurological toxicities, and the practical aspects of their administration; explain the rationale and optimum strategies for the use of these agents in a wide spectrum of primary and secondary nervous system disorders; establish a safe and efficient office-based program for the use of immunosuppressive and myelosuppressive therapies in patients with nervous system diseases; develop algorithms for treatment and monitoring and apply standardized metrics for assessing outcome; and discuss the evolving role of immune system ablation in the treatment of immune-mediated nervous system disorders such as multiple sclerosis, Behçet's disease, and Sneddon's syndrome.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
09:00 AM - 09:35 AM		Immunosuppressive Therapy in Demyelinating Disease: How I Do It Patricia K. Coyle, MD, F�鶹��ýӳ��
09:35 AM - 10:10 AM		Immunosuppressive Therapy in Neuromuscular Disease: How I Do It Marinos C. Dalakas, MD, F�鶹��ýӳ��
10:10 AM - 10:45 AM		Rebooting the Immune System: To Transplant or Replant Douglas A. Kerr, MD, PhD
10:45 AM - 11:00 AM		Break
11:00 AM - 11:30 AM		Managing the Toxicities of Immunusuppression in the Office Setting I Michael Glantz, MD, F�鶹��ýӳ��
11:30 AM - 12:00 PM		Managing the Toxicities of Immunosuppression in the Office Setting II Camilo E. Fadul, MD, F�鶹��ýӳ��
12:00 PM - 12:20 PM		Case Presentations: Demyelinating Disease Patricia K. Coyle, MD, F�鶹��ýӳ��
12:20 PM - 12:40 PM		Case Presentations: Neuromuscular Disease Marinos C. Dalakas, MD, F�鶹��ýӳ��

Faculty Disclosures
Michael Glantz, MD, F�鶹��ýӳ��	No disclosure on file
Patricia K. Coyle, MD, F�鶹��ýӳ��	Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Coyle has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi Genzyme. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GlaxoSmithKline. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. The institution of Dr. Coyle has received research support from CorEvitas LLC. The institution of Dr. Coyle has received research support from Genentech/Roche. The institution of Dr. Coyle has received research support from NINDS. The institution of Dr. Coyle has received research support from Sanofi Genzyme. The institution of Dr. Coyle has received research support from Cleveland Clinic.
Marinos C. Dalakas, MD, F�鶹��ýӳ��	Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for �鶹��ýӳ��. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.
Daniel B. Drachman, MD, F�鶹��ýӳ��	No disclosure on file
Camilo E. Fadul, MD, F�鶹��ýӳ��	No disclosure on file
Douglas A. Kerr, MD, PhD	Dr. Kerr has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Trace Neuroscience. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Spolia Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for AAVantgarde Therrapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Trace Neuroscience. Dr. Kerr has or had stock in Dyne Therapeutics.